Insider Buying: Charles O’keeffe Buys 10,000 Shares of Catalyst Pharmaceutical Partners Stock (CPRX)

Share on StockTwits

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Director Charles O’keeffe acquired 10,000 shares of the stock on the open market in a transaction that occurred on Wednesday, February 5th. The shares were purchased at an average cost of $1.81 per share, for a total transaction of $18,100.00. Following the completion of the transaction, the director now directly owns 177,126 shares of the company’s stock, valued at approximately $320,598. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.78 on Friday. Catalyst Pharmaceutical Partners has a one year low of $0.41 and a one year high of $3.65. The stock’s 50-day moving average is $2.00 and its 200-day moving average is $1.96. The company’s market cap is $96.4 million.

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last released its earnings data on Thursday, November 14th. The company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.07). Analysts expect that Catalyst Pharmaceutical Partners will post $-0.32 EPS for the current fiscal year.

A number of research firms have recently commented on CPRX. Analysts at Aegis reiterated a “buy” rating on shares of Catalyst Pharmaceutical Partners in a research note to investors on Wednesday, January 8th. Analysts at Zacks downgraded shares of Catalyst Pharmaceutical Partners from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, November 19th. They now have a $1.90 price target on the stock.

Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.

Receive News & Ratings for Catalyst Pharmaceutical Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Immunomedics Earns “Buy” Rating from Panmure Gordon
Immunomedics Earns “Buy” Rating from Panmure Gordon
Ford Motor Company Earns “Buy” Rating from S&P Equity Research
Ford Motor Company Earns “Buy” Rating from S&P Equity Research
The Weir Group PLC Cut to Hold at Canaccord Genuity
The Weir Group PLC Cut to Hold at Canaccord Genuity
Panmure Gordon Reaffirms Hold Rating for Wolseley plc
Panmure Gordon Reaffirms Hold Rating for Wolseley plc
Wolseley plc Earns “Overweight” Rating from Barclays
Wolseley plc Earns “Overweight” Rating from Barclays
Numis Securities Ltd Reiterates “Buy” Rating for Fresnillo Plc
Numis Securities Ltd Reiterates “Buy” Rating for Fresnillo Plc


Leave a Reply

 
© 2006-2014 Mideast Time.